Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma
Pigment Cell & Melanoma Research · 2025-07 · 38 (4)
DOI: 10.1111/pcmr.70030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, online erschienen am 02.06.2025. Verfasst von Matthew C Mannino und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin-Madison, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Melanoma, Microfluidics, Microfluidic Analytical Techniques. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH National Center for Advancing Translational Sciences (NCATS), NCATS NIH HHS.
Abstract (Originalsprache)
Circulating tumor cells (CTCs) can provide non‐invasive insight into how a cancer patient responds to therapy. Their role in disease monitoring of advanced melanoma patients treated with immune checkpoint inhibitors (ICI) is unknown. CTC protein expression of human leukocyte antigen class‐I (HLA I) and programmed death ligand‐1 (PD‐L1) may give insight into how a patient's disease evolves over the course of treatment. In our study, we utilize microfluidic Exclusion‐based Sample Preparation (ESP) technology to isolate and characterize CTCs from patients with advanced‐stage melanoma. CTC samples from melanoma patients are collected, captured, and stained. A range of 2 to 35 CTCs is observed in a cohort of 16 samples from 10 advanced‐stage melanoma patients treated with ICI therapy. Single‐cell protein expression data is generated from image cytometry analysis and used to calculate mean HLA I and PD‐L1 expression. Using our ESP capture approach, we successfully detect phenotypic and numerical heterogeneity in CTCs from melanoma patients. Our assay shows sufficient capture sensitivity and promising prognostic and predictive information, as we illustrate in our case example. A greater clinical sample size will be necessary to confirm the diagnostic sensitivity and specificity of the assay in predicting clinical outcomes for patients with advanced‐stage melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Division of Hematology, Department of Medicine, Medical Oncology, and Palliative Care, University of Wisconsin-Madison, Madison, Wisconsin, USA.
ORCID-Profile: Vincent T Ma
Förderung
- NCI NIH HHS
- NIH National Center for Advancing Translational Sciences (NCATS)
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Mannino, M. C., Zhao, S. G., Gibbs, B. K., Schehr, J. L., Fernandez, I. G., Eyzaguirre, D. A., Hintz, A. M., Davis, S. J., Vatani, M. N., Caceres, J. C., Birbrair, A., Lang, J. M., & Ma, V. T. (2025). Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma. Pigment Cell & Melanoma Research, 38(4). https://doi.org/10.1111/pcmr.70030
Vancouver
Mannino MC, Zhao SG, Gibbs BK, Schehr JL, Fernandez IG, Eyzaguirre DA, et al. Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma. Pigment Cell & Melanoma Research. 2025;38(4). doi:10.1111/pcmr.70030
BibTeX
@article{Mannino2025,
author = {Mannino, Matthew C and Zhao, Shuang G and Gibbs, Benjamin K and Schehr, Jennifer L and Fernandez, Isabella G and Eyzaguirre, Diego A and Hintz, Alyssa M and Davis, Stephanie J and Vatani, Manushi N and Caceres, Jacob C and Birbrair, Alexander and Lang, Joshua M and Ma, Vincent T},
title = {Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma},
journal = {Pigment Cell & Melanoma Research},
year = {2025},
volume = {38},
number = {4},
doi = {10.1111/pcmr.70030}
}
EUVIMED